DocGo: Director Klasko to step down; Burdiek named independent Chair; special committee for cost reduction

DocGo Inc.

Dr. Stephen Klasko will step down from the Board effective after the 2026 Annual Meeting on June 16, 2026, due to a new healthcare leadership role.
Klasko's departure was not due to any disagreement with DocGo regarding operations, disclosures, policies, or practices.
Michael Burdiek, an independent director, was appointed as independent Chair of the Board, effective at the same time as Klasko's departure.
Jim Travers was appointed to the Audit and Compliance Committee and the Nominating and Corporate Governance Committee, replacing Klasko immediately prior to the effective time.
On April 21, 2026, the Board formed a special committee (Vina Leite, Ira Smedra, Michael Burdiek) to identify corporate efficiencies and cost reduction opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.